Medically reviewed by Drugs.com. Last updated on Feb 9, 2023.
Premenstrual Dysphoric Disorder
The recommended dose of SARAFEM for the treatment of PMDD is 20 mg/day given continuously (every day of the menstrual cycle) or intermittently (defined as starting a daily dose 14 days prior to the anticipated onset of menstruation through the first full day of menses and repeating with each new cycle). The dosing regimen should be determined by the physician based on individual patient characteristics. In a study comparing continuous dosing of fluoxetine 20 and 60 mg/day to placebo, both doses were proven to be effective, but there was no statistically significant added benefit for the 60–mg/day compared with the 20–mg/day dose. Fluoxetine doses above 60 mg/day have not been systematically studied in patients with PMDD. The maximum fluoxetine dose should not exceed 80 mg/day.
As with many other medications, a lower or less frequent dosage should be considered in patients with hepatic impairment. A lower or less frequent dosage should also be considered for patients with concurrent disease or on multiple concomitant medications. Dosage adjustments for renal impairment are not routinely necessary (see Liver disease and Renal disease under CLINICAL PHARMACOLOGY, and Use in Patients with Concomitant Illness under PRECAUTIONS).
Systematic evaluation of SARAFEM has shown that its efficacy in PMDD is maintained for periods of up to 6 months at a dose of 20 mg/day given continuously and up to 3 months at a dose of 20 mg/day given intermittently (see CLINICAL TRIALS). Patients should be periodically reassessed to determine the need for continued treatment.
Treatment of Pregnant Women During the Third Trimester
Neonates exposed to fluoxetine and other SSRIs or SNRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with fluoxetine during the third trimester, the physician should carefully consider the potential risks and benefits of treatment. The physician may consider tapering fluoxetine in the third trimester.
Discontinuation of Treatment with SARAFEM
Symptoms associated with discontinuation of SARAFEM and other SSRIs and SNRIs, have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and norfluoxetine concentration decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.
Frequently asked questions
- SSRI’s vs SNRI’s - What's the difference between them?
- Is Prozac (fluoxetine) safe for dogs?
- Prozac vs Zoloft - What are the Differences & Similarities?
- What are some common side effects of antidepressants?
- Taking fluoxetine, what can I use for a bad cough from cold or strep throat?
More about Sarafem (fluoxetine)
- Check interactions
- Compare alternatives
- Reviews (22)
- Drug images
- Side effects
- During pregnancy
- Drug class: selective serotonin reuptake inhibitors
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.